The US regulator has approved Sanofi/Regeneron’s Dupixent (dupilumab) in a new asthma indication, a key step in the companies attempt to build a blockbuster franchise around the drug.
Trials of Sanofi and Regeneron’s drug Dupixent (dupilumab) have shown positive results for treating patients suffering from chronic rhinosinusitis with nasal polyps, teeing up a potential n
Novo Nordisk is to launch “connected” insulin pens, responding for demands from patients for devices able to communicate with glucose monitoring systems and glucose meters.
Sanofi has revealed details of research, which forms the basis of filings to extend the use of its eczema drug Dupixent (dupilumab) so it can be used to treat adolescents.